X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (98933) 98933
Publication (7652) 7652
Newspaper Article (4850) 4850
Patent (1527) 1527
Book Review (852) 852
Newsletter (601) 601
Book Chapter (593) 593
Magazine Article (536) 536
Trade Publication Article (353) 353
Conference Proceeding (321) 321
Dissertation (181) 181
Book / eBook (113) 113
Web Resource (34) 34
Government Document (21) 21
Streaming Video (20) 20
Reference (15) 15
Paper (9) 9
Data Set (8) 8
Transcript (6) 6
Journal / eJournal (5) 5
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45254) 45254
animals (39874) 39874
male (34759) 34759
index medicus (25525) 25525
female (23391) 23391
calcium channel blockers - pharmacology (20730) 20730
rats (18902) 18902
pharmacology & pharmacy (15020) 15020
middle aged (14147) 14147
calcium channel blockers - therapeutic use (12321) 12321
aged (11346) 11346
hypertension (10570) 10570
cardiac & cardiovascular systems (10100) 10100
adult (9955) 9955
hypertension - drug therapy (9702) 9702
heart failure (9072) 9072
beta blockers (8963) 8963
in vitro techniques (7984) 7984
neurosciences (7594) 7594
dose-response relationship, drug (7569) 7569
calcium - metabolism (7535) 7535
blood pressure - drug effects (7420) 7420
mice (6722) 6722
treatment outcome (6210) 6210
peripheral vascular disease (6196) 6196
beta-blockers (6035) 6035
mortality (5997) 5997
rats, sprague-dawley (5767) 5767
adrenergic beta-antagonists - therapeutic use (5729) 5729
time factors (5662) 5662
antihypertensive agents - therapeutic use (5632) 5632
physiology (5453) 5453
angiotensin-converting enzyme inhibitors - therapeutic use (5390) 5390
calcium channel blockers (5161) 5161
drug therapy (5073) 5073
risk factors (5042) 5042
cells, cultured (5006) 5006
research (4740) 4740
potassium channel blockers - pharmacology (4725) 4725
rats, wistar (4696) 4696
patch-clamp techniques (4470) 4470
angiotensin ii type 1 receptor blockers - therapeutic use (4331) 4331
drug therapy, combination (4256) 4256
nifedipine - pharmacology (4196) 4196
analysis (4178) 4178
biochemistry & molecular biology (4092) 4092
medicine, general & internal (3945) 3945
hypertension - physiopathology (3883) 3883
calcium (3743) 3743
blood pressure (3701) 3701
care and treatment (3673) 3673
blood-pressure (3557) 3557
membrane potentials - drug effects (3424) 3424
calcium channel blockers - administration & dosage (3421) 3421
heart rate - drug effects (3348) 3348
nifedipine (3270) 3270
verapamil - pharmacology (3263) 3263
adrenergic beta blockers (3206) 3206
angiotensin ii type 1 receptor blockers - pharmacology (3194) 3194
cardiology (3076) 3076
electrophysiology (3052) 3052
double-blind method (3007) 3007
calcium channels (3003) 3003
potassium channel blockers (2996) 2996
therapy (2986) 2986
expression (2985) 2985
health aspects (2973) 2973
calcium channel blockers - adverse effects (2950) 2950
kinetics (2932) 2932
angiotensin (2925) 2925
rabbits (2904) 2904
disease models, animal (2893) 2893
aged, 80 and over (2863) 2863
cells (2819) 2819
neurons - drug effects (2774) 2774
calcium-channel blockers (2755) 2755
inhibition (2731) 2731
urology & nephrology (2713) 2713
medicine & public health (2676) 2676
heart (2667) 2667
blockers (2663) 2663
article (2607) 2607
double-blind (2594) 2594
sodium channel blockers - pharmacology (2553) 2553
dogs (2549) 2549
physiological aspects (2544) 2544
risk (2507) 2507
patients (2506) 2506
heart failure - drug therapy (2495) 2495
guinea pigs (2489) 2489
rat (2485) 2485
prospective studies (2478) 2478
verapamil (2469) 2469
cell biology (2459) 2459
action potentials - drug effects (2443) 2443
activation (2424) 2424
potassium channels (2387) 2387
drug interactions (2385) 2385
hypertension - complications (2339) 2339
drugs (2327) 2327
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (107) 107
Online Resources - Online (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (98007) 98007
Japanese (2211) 2211
Russian (1887) 1887
German (1565) 1565
Danish (1198) 1198
French (1051) 1051
Chinese (708) 708
Spanish (674) 674
Norwegian (550) 550
Italian (416) 416
Polish (226) 226
Korean (213) 213
Portuguese (200) 200
Czech (136) 136
Ukrainian (125) 125
Hungarian (99) 99
Swedish (81) 81
Dutch (78) 78
Slovak (68) 68
Turkish (53) 53
Finnish (28) 28
Romanian (27) 27
Croatian (20) 20
Bulgarian (19) 19
Hebrew (19) 19
Serbian (19) 19
Lithuanian (9) 9
Persian (7) 7
Slovenian (7) 7
Bosnian (5) 5
Icelandic (2) 2
Arabic (1) 1
Belarusian (1) 1
Catalan (1) 1
Greek (1) 1
Norwegian Bokmål (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 07/2015, Volume 66, Issue 1, pp. 183 - 189
Conflicting data on the relationship between antihypertensive medications and falls in elderly people may lead to inappropriate undertreatment of hypertension... 
aged | blood flow velocity | angiotensin-converting enzyme inhibitors | antihypertensive agents | calcium channel blockers | POPULATION | METAANALYSIS | INCREASES | RISK | HYPERTENSIVE PATIENTS | AUTOREGULATION | HEMODYNAMICS | PRESSURE | PERIPHERAL VASCULAR DISEASE | PEOPLE | CEREBRAL-BLOOD-FLOW | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Calcium Channel Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Adrenergic beta-Antagonists - pharmacology | Accidental Falls - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adrenergic beta-Antagonists - adverse effects | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Disease Susceptibility | Cerebrovascular Circulation - drug effects | Comorbidity | Diuretics - pharmacology | Accidents, Home - prevention & control | Antihypertensive Agents - therapeutic use | Calcium Channel Blockers - pharmacology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Diabetes Mellitus - epidemiology | Calcium Channel Blockers - administration & dosage | Diuretics - therapeutic use | Aged | Cognition Disorders - epidemiology | Diuretics - adverse effects | Life Sciences | Human health and pathology
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 04/2013, Volume 20, Issue 10, pp. 1241 - 1285
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system.... 
ASIC | TRP | Central nervous system | P2X | KCNQ | NMDA | CNS | Ion channels | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | GATED SODIUM-CHANNELS | SUBTYPE-SELECTIVE AGONIST | D-ASPARTATE RECEPTOR | ion channels | ACID-SENSING ION-CHANNEL-1 | central nervous system | GLYCINE ANTAGONIST GV150526 | TARANTULA TOXIN PSALMOTOXIN-1 | TRAUMATIC BRAIN-INJURY | ISCHEMIC CELL-DEATH | PHARMACOLOGY & PHARMACY | PERIPHERAL NEUROPATHIC PAIN | TRANSGENIC MOUSE MODEL | Ligand-Gated Ion Channels - antagonists & inhibitors | Transient Receptor Potential Channels - antagonists & inhibitors | Calcium Channels - metabolism | Humans | Calcium Channel Blockers - therapeutic use | Potassium Channel Blockers - therapeutic use | Sodium Channel Blockers - pharmacology | Calcium Channel Blockers - pharmacology | Ion Channels - antagonists & inhibitors | Potassium Channels - metabolism | Animals | Ion Channels - metabolism | Sodium Channels - chemistry | Calcium Channels - chemistry | Central Nervous System Diseases - drug therapy | Sodium Channels - metabolism | Calcium Channel Blockers - chemistry | Sodium Channel Blockers - therapeutic use | Potassium Channels - chemistry | Sodium Channel Blockers - chemistry | Transient Receptor Potential Channels - metabolism | Ligand-Gated Ion Channels - metabolism | Potassium Channel Blockers - chemistry | Potassium Channel Blockers - pharmacology
Journal Article
Annual Review of Pharmacology and Toxicology, ISSN 0362-1642, 1/2015, Volume 55, Issue 1, pp. 333 - 352
The four major classes of antihypertensive drugs-diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including... 
angiotensin-converting enzyme inhibitors | β-blockers | angiotensin receptor blockers | calcium channel blockers | diuretics | hypertension | Angiotensin-converting enzyme inhibitors | Hypertension | Diuretics | Calcium channel blockers | Angiotensin receptor blockers | CLINICAL-PHARMACOLOGY | CARDIOVASCULAR EVENTS | HEART-FAILURE | beta-blockers | CONVERTING ENZYME-INHIBITORS | BLOOD-PRESSURE REDUCTION | CANADIAN HYPERTENSION | CALCIUM-CHANNEL BLOCKERS | ANGIOTENSIN-RECEPTOR BLOCKERS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CORONARY-ARTERY-DISEASE | Adrenergic beta-Antagonists - classification | Angiotensin-Converting Enzyme Inhibitors - classification | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Treatment Outcome | Structure-Activity Relationship | Antihypertensive Agents - classification | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - chemistry | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers - classification | Hypertension - complications | Calcium Channel Blockers - classification | Diuretics - therapeutic use | Blood Pressure - drug effects | Molecular Structure | Diuretics - classification | Adrenergic beta-Antagonists - therapeutic use | Index Medicus
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | ACTION-POTENTIALS | TORSADES-DE-POINTES | DOFETILIDE | CONTRACTILITY | drug-induced proarrhythmia | PROLONGATION | LONG-QT SYNDROME | VENTRICULAR MYOCYTES | MATURATION | IMPEDANCE | TOXICOLOGY | batch variations | RISK-ASSESSMENT | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects
Journal Article
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 03/2019, Volume 90, Issue 3, pp. e13 - e13
ObjectivesTo analyse long-term adverse events of occipital nerve stimulation (ONS).DesignProspective open-label observational study.Subjects134 patients with... 
Beta blockers
Journal Article
Biochemistry, ISSN 0006-2960, 12/2002, Volume 41, Issue 50, pp. 14734 - 14747
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 1997, Volume 29, Issue 4, pp. 563 - 580
Journal Article
Drugs, ISSN 0012-6667, 10/2016, Volume 76, Issue 16, pp. 1529 - 1550
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications... 
C-REACTIVE PROTEIN | CONVERTING ENZYME-INHIBITION | NITRIC-OXIDE SYNTHASE | ORAL VITAMIN-C | PHARMACOLOGY & PHARMACY | SMOOTH-MUSCLE-CELLS | ANGIOTENSIN-II | TOXICOLOGY | FLOW-MEDIATED DILATION | CENTRAL BLOOD-PRESSURE | CORONARY-ARTERY-DISEASE | ENDOTHELIUM-DEPENDENT VASODILATION | Antihypertensive Agents - pharmacology | Cerebrovascular Disorders - drug therapy | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Angiotensin Receptor Antagonists - pharmacology | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Renal Insufficiency - drug therapy | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Angiotensin Receptor Antagonists - chemistry | Risk Factors | Antihypertensive Agents - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - chemistry | Heart Failure - drug therapy | Antihypertensive Agents - chemistry | Calcium Channel Blockers - administration & dosage | Calcium Channel Blockers - chemistry | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - administration & dosage
Journal Article